Alfasigma Deal History & Licensing Activity
Alfasigma is a life sciences. Over the past three years, Alfasigma has been involved in 3 licensing and acquisition transactions, with a primary focus on Small Molecules (3 deals). The company currently has 9 active clinical trials, primarily in Autoimmune.
Deals (12mo)
1
Active Trials
9
Top Modality
Small Molecules
Focus Area
Autoimmune
Alfasigma Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Alfasigma in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| linerixibat | GSK | Small Molecules | Phase 3 | license | Mar 2026 |
Alfasigma Pipeline Focus
Therapeutic areas and modalities where Alfasigma is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Alfasigma Strategic Signals
Key indicators of Alfasigma's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Alfasigma Clinical Pipeline
Alfasigma has 9 active clinical trials across 4 development phases.
4
Unknown
1
Phase 1
1
Phase 2
3
Phase 3
See How Your Asset Matches Alfasigma's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Autoimmune assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Gastroenterology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for gastroenterology
Metabolic Deal Benchmarks
Market sizing, deal terms, and competitive landscape for metabolic
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
About Alfasigma Licensing & Deal Activity
Alfasigma is a life sciences company that has been actively engaged in licensing transactions across the biopharma landscape. With 3 deals over the past three years, Alfasigma ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Alfasigma include Autoimmune (6 deals and trials), Gastroenterology (3 deals and trials), Metabolic (1 deal and trial), and Solid Tumors (1 deal and trial). In terms of modality, Alfasigma has shown particular interest in small molecules, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Alfasigma and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Alfasigma's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.